An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV
- Watkins, Jennifer D. Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America - Harvard Medical School, Boston, Massachusetts, United States of America
- Siddappa, Nagadenahalli B. Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America - Harvard Medical School, Boston, Massachusetts, United States of America
- Lakhashe, Samir K. Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America - Harvard Medical School, Boston, Massachusetts, United States of America
- Humbert, Michael Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America - Harvard Medical School, Boston, Massachusetts, United States of America
- Sholukh, Anton Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America - Harvard Medical School, Boston, Massachusetts, United States of America
- Hemashettar, Girish Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- Wong, Yin Ling Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- Yoon, John K. Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- Wang, Wendy Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- Novembre, Francis J. Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America - Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, United States of America
- Villinger, Francois Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America - Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America
- Ibegbu, Chris Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America
- Patel, Kalpana Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America
- Corti, Davide Humabs SAGL, Bellinzona, Switzerland
- Agatic, Gloria Humabs SAGL, Bellinzona, Switzerland
- Vanzetta, Fabrizio Humabs SAGL, Bellinzona, Switzerland
- Bianchi, Siro Humabs SAGL, Bellinzona, Switzerland
- Heeney, Jonathan L. Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
- Sallusto, Federica Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
- Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
- Ruprecht, Ruth M. Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America - Harvard Medical School, Boston, Massachusetts, United States of America
-
31.03.2011
Published in:
- Plos one. - 2011, vol. 6, no. 3, p. e18207
English
Neutralizing antibodies have been shown to protect macaques against SHIV challenge. However, genetically diverse HIV-1 clades have evolved, and a key question left unanswered is whether neutralizing antibodies can confer cross-clade protection in vivo. The novel human monoclonal antibody HGN194 was isolated from an individual infected with an HIV-1 clade AG recombinant circulating recombinant form (CRF). HGN194 targets an epitope in the third hypervariable loop (V3) of HIV-1 gp120 and neutralizes a range of relatively neutralization- sensitive and resistant viruses. We evaluated the potential of HGN194 to protect infant rhesus monkeys against a SHIV encoding a primary CCR5-tropic HIV-1 clade C envelope. After high- dose mucosal challenge, all untreated controls became highly viremic while all HGN194-treated animals (50 mg/kg) were completely protected. When HGN194 was given at 1 mg/kg, one out of two monkeys remained aviremic, whereas the other had delayed, lower peak viremia. Interestingly, all protected monkeys given high-dose HGN194 developed Gag-specific proliferative responses of both CD4+ and CD8+ T cells. To test whether generation of the latter involved cryptic infection, we ablated CD8+ cells after HGN194 clearance. No viremia was detected in any protected monkeys, thus ruling out virus reservoirs. Thus, induction of CD8 T-cell immunity may have resulted from transient “Hit and Run” infection or cross priming via Ag-Ab- mediated cross-presentation. Together, our data identified the HGN194 epitope as protective and provide proof-of-concept that this anti-V3 loop mAb can prevent infection with sterilizing immunity after challenge with virus of a different clade, implying that V3 is a potential vaccine target.
- Language
-
- English
- Classification
- Medicine
- License
- License undefined
- Identifiers
-
- RERO DOC 326634
- DOI 10.1371/journal.pone.0018207
- ARK ark:/12658/srd1319009
- Persistent URL
- https://n2t.net/ark:/12658/srd1319009
Statistics
Document views: 31
File downloads:
- watkins_pone_2011.pdf: 39